Background: Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase inhibitors, which interfere with DNA damage repair. Veliparib, a potent poly(ADP-ribose) polymerase inhibitor, enhanced the antitumor activity of platinum agents and temozolomide in early phase clinical trials. This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer.
Background: Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase inhibitors, which interfere with DNA damage repair. Veliparib, a potent poly(ADP-ribose) polymerase inhibitor, enhanced the antitumor activity of platinum agents and temozolomide in early phase clinical trials. This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer.
Patients and methods:
Eligible patients 18 years with locally recurrent or metastatic breast cancer and a deleterious BRCA1/ 2 germline mutation were randomized 1 : 1 : 1 to VCP, VT, or placebo plus carboplatin/paclitaxel (PCP). Primary end point was progression-free survival (PFS); secondary end points included overall survival (OS) and overall response rate (ORR).
Results: Of 290 randomized patients, 284 were BRCAþ, confirmed by central laboratory. For VCP versus PCP, median PFS was 14.1 and 12.3 months, respectively [hazard ratio (HR) 0.789; 95% CI 0.536-1.162; P ¼ 0.227], interim median OS 28.3 and 25.9 months (HR 0.750; 95% CI 0.503-1.117; P ¼ 0.156), and ORR 77.8% and 61.3% (P ¼ 0.027). For VT (versus PCP), median PFS was 7.4 months (HR 1.858; 95% CI 1.278-2.702; P ¼ 0.001), interim median OS 19.1 months (HR 1.483; 95% CI 1.032-2.131; P ¼ 0.032), and ORR 28.6% (P < 0.001). Safety profile was comparable between carboplatin/paclitaxel arms. Adverse events (all grades) of neutropenia, anemia, alopecia, and neuropathy were less frequent with VT versus PCP.
Conclusion: Numerical but not statistically significant increases in both PFS and OS were observed in patients with BRCA1/2-mutated recurrent/metastatic breast cancer receiving VCP compared with PCP. The addition of veliparib to carboplatin/paclitaxel significantly improved ORR. There was no clinically meaningful increase in toxicity with VCP versus PCP. VT was inferior to PCP. An ongoing phase III trial is evaluating VCP versus PCP, with optional continuation single-agent therapy with veliparib/placebo if chemotherapy is discontinued without progression, in this patient population.
Introduction
Mutations in BRCA1/2 genes are the most common inherited mutations associated with breast cancer [1] . The homologous recombination DNA damage repair pathway is defective in BRCAþ tumor cells. Poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 function in detecting and repairing DNA damage [2] , and PARP inhibitors are synthetic lethal in cells with DNA damage defects [3, 4] . Monotherapy with PARP inhibitors has antitumor activity in patients with BRCAþ cancers; PARP inhibitors have gained regulatory approval in patients with ovarian cancer [5] [6] [7] .
Veliparib (ABT-888) is a potent, orally bioavailable, selective PARP-1/2 inhibitor that crosses the blood-brain barrier [8] . Veliparib monotherapy has demonstrated antitumor activity in BRCAþ patients [5] and has shown promising results in combination with DNA-damaging therapies in early phase clinical trials. In a phase I dose-escalation study of veliparib plus carboplatin/ paclitaxel, the objective response rate (ORR) was 57% (8/14) among patients with metastatic breast cancer receiving the maximum administered dose of veliparib [9] . Tolerability of veliparib with carboplatin/paclitaxel was comparable with that expected for carboplatin/paclitaxel alone [9] . These results, along with recent data indicating platinum sensitivity among BRCAþ patients [10, 11] , suggest veliparib plus platinum may be an effective therapy for patients with BRCAþ breast cancer.
In a phase II study examining veliparib plus temozolomide in patients with metastatic breast cancer, response rate was 25% (7/28) and clinical benefit rate (CBR) 50% among BRCAþ patients [12, 13] . While single-agent temozolomide has limited activity in breast cancer [14] , these data suggest the combination may provide patients with BRCA-mutated metastatic breast cancer a novel all-oral regimen with reduced hematologic toxicities and alopecia compared with other combination regimens.
Here, we report primary results of the BROCADE study evaluating safety and efficacy of intermittent veliparib with temozolomide (VT) or veliparib with carboplatin/paclitaxel (VCP) compared with placebo plus carboplatin/paclitaxel (PCP) in the biomarker-selected population of BRCAþ patients with locally recurrent or metastatic breast cancer.
Patients and methods
BROCADE is a randomized, partially blinded phase II trial (NCT01506609) at 86 sites in 20 countries. The study was approved by an independent ethics committee/independent review board at each site and carried out in accordance with the Declaration of Helsinki. Patients provided written informed consent.
Patients
Eligible patients were 18 years of age with histologically or cytologically confirmed locally recurrent or metastatic breast cancer with a deleterious BRCA1/2 germline mutation. Human epidermal growth factor receptor 2 mutation-positive (HER2þ) patients were enrolled if they were ineligible for or progressed on prior HER2-directed therapy. Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, radiologically evaluable disease, and adequate hematologic, renal, and hepatic function. Exclusion criteria included >2 prior lines of cytotoxic therapy for metastatic disease, prior breast cancer treatment with temozolomide, platinum, or PARP inhibitor, prior taxane for metastatic breast cancer (unless patient received 1 cycle or therapy was >1 year before enrollment), pre-existing neuropathy grade >1, and history of brain metastases or uncontrolled seizure disorder.
Treatment
Patients were randomized 1 : 1 : 1 to PCP, VCP, or VT. Randomization was stratified by hormone receptor status [estrogen receptor (ER) and/or progesterone receptor (PgR) positive, ER and/or PgR negative], prior cytotoxic therapy (yes, no), and ECOG performance status (0-1, 2). The carboplatin/paclitaxel arms were double-blinded; treatment was openlabel for the VT arm. Placebo/veliparib dose was 120 mg BID orally on days 1-7 (21-day cycle) in the carboplatin/paclitaxel arms. Carboplatin (area under the curve 6 mg/ml/min) and paclitaxel (175 mg/m 2 ) were administered intravenously on day 3. In the VT arm, veliparib dose was 40 mg BID orally on days 1-7. Temozolomide started at 150 mg/m 2 QD orally on days 1-5 (28-day cycle), and was escalated to 200 mg/m 2 at cycle 2 if well-tolerated during the first cycle. Treatment was until disease progression or unmanageable toxicity. Veliparib/placebo could be continued if either carboplatin or paclitaxel was discontinued for toxicity, but veliparib/placebo was discontinued if both carboplatin and paclitaxel were discontinued. If either veliparib or temozolomide was discontinued because of toxicity, both were discontinued.
On-study evaluation
Tumor response was assessed by computed tomography scan utilizing Response Evaluation Criteria in Solid Tumors v1.1 at screening, 9-week intervals thereafter, and final visit. Post-treatment and survival information was collected monthly after discontinuation. Adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.
Statistical methodology and end point analysis
Primary efficacy end point was progression-free survival (PFS) by independent central review. Secondary end points included overall survival (OS), ORR, and CBR (progression-free rate at week 18).
The study enrolled 290 patients to accrue 159 total PFS events (112 on carboplatin/paclitaxel arms) and 194 total OS events (136 on carboplatin/paclitaxel arms) to provide 80% power at two-sided a ¼ 0.05 [assuming a hazard ratio (HR) of 0.58 and 0.61 for PFS and OS, respectively] to detect a statistically significant treatment effect for VCP versus PCP or for VT versus PCP.
Results of the primary analysis are reported, with interim OS (164 deaths). Efficacy analyses included all randomized patients with deleterious germline BRCA1/2 mutations confirmed by central laboratory (Myriad). Safety analyses included patients receiving 1 dose of study drug. The log-rank test, stratified by ER/PgR status and prior cytotoxic therapy, compared PFS and OS between each veliparib-containing arm and the placebo arm. CBR was estimated and compared using KaplanMeier estimates. ORR was estimated and compared using the CochranMantel-Haenszel test stratified by ER/PgR status and prior cytotoxic therapy. Comparisons of safety data used Fisher's exact test. Statistical significance was determined by a two-sided P value 0.05. Analyses were carried out using SAS v9.2 or higher (SAS Institute, Inc., Cary, NC) under the UNIX operating system. Additional details are available in Supplementary Methods at Annals of Oncology online.
Results

Patient characteristics
Two hundred ninety-four patients were randomized between January 2012 and April 2015 (supplementary Figure S1 , available at Annals of Oncology online). Four patients in the carboplatin/ paclitaxel arms received veliparib/placebo at 80 mg BID and were excluded from efficacy analyses per protocol. Of the 290 patients randomized after this amendment (VCP, N ¼ 97; PCP, N ¼ 99; VT, N ¼ 94), 282 received 1 dose of study drug, and 284 had a centrally confirmed deleterious BRCA1/2 mutation. Baseline patient characteristics are in Table 1 .
Efficacy
Median PFS for VCP and PCP was 14.1 months (95% CI 11. Table 2 ). Duration of overall response among patients receiving VT was 6.3 months (95% CI 4.2-12.4). Among 76 patients with PFS events, 3 had new central nervous system metastases.
Treatment exposure and tolerability
Median (range) veliparib/placebo exposure for PCP and VCP arms was 10 (1-33) cycles and 12 (1-48) cycles, respectively. For PCP and VCP, median (range) carboplatin exposure was 9 (1-31) and 9 (1-42) cycles, and paclitaxel exposure was 9 (1-33) and 9 (1-48) cycles. For VT, median (range) exposure was 6 (1-26) cycles for veliparib and temozolomide.
The most common any grade treatment-emergent adverse events with PCP versus VCP were neutropenia (74.0% and 74.2%, respectively), thrombocytopenia (69.8% and 71.0%), and nausea (58.3% and 71.0%) [P ¼ not significant (NS) for each comparison] (Table 3) . Grade 3/4 adverse events in 30% of patients treated with PCP or VCP were neutropenia (55.2% and 55.9%) and thrombocytopenia (26.0% and 31.2%) (P ¼ NS for each comparison). Rates of veliparib/placebo, carboplatin, and paclitaxel interruption, dose reduction, and discontinuation due to adverse events were comparable between the two carboplatin/ paclitaxel-containing arms (P ¼ NS) (supplementary Table S1 , available at Annals of Oncology online). Fifty-two patients (52.5%) in the PCP arm and 51 (52.6%) in the VCP arm received colony-stimulating factors at some point. The serious adverse event rate was 27.1% for PCP and 34.4% for VCP (P ¼ NS).
In the VT arm, the most common any grade treatmentemergent adverse events were neutropenia (49.5%), thrombocytopenia (78.5%), and nausea (75.3%). Nausea occurred more frequently with VT than PCP (P ¼ 0.014), while anemia (P < 0.01), alopecia (P < 0.001), neutropenia (P < 0.001), and neuropathy (P < 0.001) occurred less frequently. Nineteen (20.2%) patients in the VT arm received colony-stimulating factors. Temozolomide was escalated from 150 to 200 mg/kg 2 at cycle 2 in 36% of patients. The serious adverse event rate was 17.2% for VT, comparable with the rate for PCP (P ¼ NS).
Discussion
BROCADE evaluated veliparib combined with two different chemotherapy backbones in patients with BRCAþ locally recurrent/metastatic breast cancer. Numerical increases in PFS and OS were observed with VCP compared with carboplatin/paclitaxel alone, although these did not meet statistical significance. The addition of veliparib to carboplatin/paclitaxel significantly improved ORR from 61.3% to 77.8% (P ¼ 0.027).
Carboplatin/paclitaxel was highly active, supporting emerging data indicating sensitivity of BRCAþ breast cancer to platinum [10, 11] . In a study examining carboplatin or docetaxel as firstline metastatic therapy in patients with TNBC or BRCAþ breast cancer, PFS was 6.8 months for carboplatin and 4.8 months for docetaxel in BRCAþ patients [11] . A phase III trial explored olaparib monotherapy in patients with BRCAþ metastatic breast cancer who had 2 previous chemotherapy regimens for metastatic disease and prior anthracycline/taxane treatment; median PFS was 7.0 months and median OS was 19.3 months [15] . Median PFS was 12.3 months for PCP and 14.1 months for VCP and median OS was 25.9 months for PCP and 28.3 months for VCP in our study of predominantly first-line metastatic patients. Although patient populations and treatment durations were not standard across these three trials, these extended PFS times suggest durable disease control is achievable with PCP and VCP combination regimens. This response needs to be balanced with tolerability and quality of life, and it will be important to consider quality of life and patient-reported outcomes in future analyses. Patients in this study remained on study treatment of a median 10 cycles of PCP and 12 cycles of VCP, with ranges up to 48 cycles.
The VCP safety profile was comparable with that of PCP. Patients receiving VCP did not experience more veliparib/placebo, carboplatin, or paclitaxel dose reductions, discontinuations, or interruptions than patients receiving placebo. While a previous report evaluating carboplatin/paclitaxel with or without the PARP inhibitor olaparib indicated an increase in any-grade neutropenia among patients receiving olaparib [16] , the incidence of neutropenia was essentially unchanged by the addition of veliparib to carboplatin/paclitaxel in the current study. Duration of exposure to veliparib/placebo, carboplatin, and paclitaxel was comparable whether patients were randomized to veliparib or placebo.
PFS, OS, and ORR were each inferior with VT compared with PCP. However, 73.0% of patients experienced clinical benefit, and 28.6% had an objective response. Although VT was not compared with a single-agent control, these responses are notable because of the reported limited activity of single-agent temozolomide in patients with breast cancer (although BRCA status of patients in this previous trial is unknown) [14] . In the VT arm, veliparib was dosed intermittently at 40 mg BID (based on phase I/II trial experience with this combination). This is a potentially low dose for combinatorial efficacy; 400 mg BID is the recommended phase II monotherapy dose [12, 17, 18] . The VT regimen provided tolerability advantages over PCP, with less frequent neutropenia, anemia, alopecia, and neuropathy. Given the tolerability profile, an all-oral regimen like VT may be suitable for selected patients unable or unwilling to be treated with intravenous platinum-based combination chemotherapy regimens. Emerging data indicate that PARP inhibitors function through both inhibition of PARP activity and 'trapping' of PARP at sites of DNA damage. The relative contribution of these mechanisms to PARP inhibitor function may be context dependent. Trapping has been reported in cells treated with PARP inhibitors and alkylating agents [19] . However, the same has not been observed with PARP inhibitors and platinum agents [19, 20] . These data suggest the lower trapping efficiency of veliparib [20, 21] , may not be impactful for its efficacy as part of the VCP regimen. Data have also suggested that trapping efficiency and tolerability are inversely related [22] , which may limit the tolerability of higher efficiency trapping agents in similar regimens [23] .
The current study was limited by the small sample size, based upon aggressive HR assumption of 0.58 for PFS and 0.61 for OS. The ongoing phase III study investigating veliparib added to carboplatin/paclitaxel in a larger BRCAþ breast cancer population will have greater power to detect a difference. Furthermore, there was no single-agent veliparib/placebo option for patients discontinuing chemotherapy. For several patients receiving PCP or VCP who had a CR or PR with a large tumor reduction at multiple assessments, reasons for treatment discontinuation included the very good response or to pursue less intense alternate therapy.
In a recently reported phase III trial in the neoadjuvant breast cancer setting, veliparib did not improve the efficacy of Figure 1 . Kaplan-Meier curve of (A) progression-free survival and (B) overall survival. NR, not reached; OS, overall survival; PCP, placebo plus carboplatin/paclitaxel; PFS, progression-free survival; VCP, veliparib plus carboplatin/paclitaxel; VT, veliparib plus temozolomide.
platinum-based chemotherapy in patients with TNBC [24] . Compared with the phase III neoadjuvant TNBC trial, the current trial and ongoing phase III trial of veliparib in advanced breast cancer enroll a more specific, biomarker-selected population of patients with germline BRCA1/BRCA2 mutations. This population has demonstrated sensitivity to PARP inhibitor therapy [15] . Furthermore, the phase III neoadjuvant TNBC study and the metastatic BRCAþ breast cancer veliparib trials use different doses of veliparib (50 mg BID continuous for 12 weeks versus 120 mg BID days 1-7 until progression, based on doses evaluated for each breast cancer type in earlier phase trials).
Patients with BRCA mutations are uniquely sensitive to both PARP inhibitors and platinum, suggesting VCP may be particularly active in this population. Platinum and PARP inhibitors share mechanisms of resistance, supporting their use in combination rather than sequentially [25] . In this phase II study, numerical trends in PFS and OS were observed with VCP over PCP, with a significant increase in ORR. The ongoing phase III trial in BRCAþ locally advanced/metastatic breast cancer (BROCADE3, NCT02163694) is powered to evaluate the efficacy of veliparib with carboplatin and weekly paclitaxel (N ¼ 500). In contrast to the phase II study, patients in the phase III trial who discontinue carboplatin/paclitaxel due to toxicity or clinical benefit can continue veliparib/placebo at the monotherapy dose (300-400 mg BID). Includes reported events of neuralgia, peripheral neuropathy, peripheral sensory neuropathy, polyneuropathy, and sensory disturbance. PCP, placebo plus carboplatin/paclitaxel; VCP, veliparib plus carboplatin/paclitaxel; VT, veliparib plus temozolomide.
